1. Home
  2. MDBH vs LITS Comparison

MDBH vs LITS Comparison

Compare MDBH & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDB Capital Holdings LLC common

MDBH

MDB Capital Holdings LLC common

N/A

Current Price

$1.85

Market Cap

23.2M

Sector

N/A

ML Signal

N/A

LITS

Lite Strategy Inc.

HOLD

Current Price

$1.18

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDBH
LITS
Founded
1997
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
36.3M
IPO Year
2022
2003

Fundamental Metrics

Financial Performance
Metric
MDBH
LITS
Price
$1.85
$1.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
★ 729.9K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 13.81
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.06
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.75
$0.69
52 Week High
$4.48
$2.26

Technical Indicators

Market Signals
Indicator
MDBH
LITS
Relative Strength Index (RSI) 28.96 46.87
Support Level N/A $1.12
Resistance Level $3.22 $1.25
Average True Range (ATR) 0.09 0.07
MACD -0.02 -0.02
Stochastic Oscillator 0.00 14.52

Price Performance

Historical Comparison
MDBH
LITS

About MDBH MDB Capital Holdings LLC common

MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.

Share on Social Networks: